Literature DB >> 11502863

Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects.

A Churg1, J Dai, K Zay, A Karsan, R Hendricks, C Yee, R Martin, R MacKenzie, C Xie, L Zhang, S Shapiro, J L Wright.   

Abstract

There is increasing evidence that antiproteases are able to affect the inflammatory response. To further examine this question, we administered human alpha-1-antitrypsin (alpha1AT) or a synthetic metalloprotease inhibitor (RS113456) to C57 mice followed by a single intratracheal dose of quartz, a dust that evokes a marked, lasting, polymorphonuclear leukocyte (PMN) infiltrate. At 2 hours after dust administration, both antiproteases completely suppressed silica-induced PMN influx into the lung and macrophage inflammatory protein-2 (MIP-2)/monocyte chemotactic protein-1 (MCP-1) (neutrophil/macrophage chemoattractant) gene expression, partially suppressed nuclear transcription factor kappaB (NF-kappaB) translocation, and increased inhibitor of NF-kappaB (IkappaB) levels. By 24 hours, PMN influx and connective tissue breakdown measured as lavage desmosine or hydroxyproline were still at, or close to, control levels after antiprotease treatment, and increases in NF-kappaB translocation and MIP-2/MCP-1 gene expression were variably suppressed. At both time points, neither agent prevented silica-induced increases in amount of whole lung MIP-2 or MCP-1 protein, but both did prevent increases in whole lung intercellular adhesion molecule-1 (ICAM-1) at 24 hours. Inactivating the alpha1AT by oxidation to the point that it no longer possessed antiproteolytic properties did not affect its ability to suppress inflammation. Both antiproteases also prevented the silica-induced acute inflammatory response in mice with knocked out genes for macrophage metalloelastase (MME -/-), mice that develop inflammation, but not connective tissue breakdown, and the pattern of alpha1AT breakdown fragments was identical in control and MME -/- animals. These findings suggest that, in this model of acute PMN mediated inflammation, a serine protease inhibitor and a metalloprotease inhibitor have similar anti-inflammatory properties, that inflammation is not mediated by proteolysis with generation of chemotactic matrix fragments, and that classic antiproteolysis (complexing of protease to antiprotease) probably does not play a role in suppression of inflammation. The antiproteolytic effects of these agents do not seem to be mediated by protection of endogenous alpha1AT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502863     DOI: 10.1038/labinvest.3780324

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  52 in total

1.  S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.

Authors:  Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew
Journal:  Cancer Res       Date:  2012-03-08       Impact factor: 12.701

Review 2.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

3.  Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin.

Authors:  Rubin M Tuder; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

4.  Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes.

Authors:  Gordon C Weir; Maria Koulamnda
Journal:  Curr Diab Rep       Date:  2009-04       Impact factor: 4.810

5.  Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis.

Authors:  Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 6.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

7.  Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus.

Authors:  Akintunde O Akinkuolie; Aruna D Pradhan; Julie E Buring; Paul M Ridker; Samia Mora
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

8.  alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.

Authors:  Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

9.  Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Authors:  Maria Koulmanda; Manoj Bhasin; Lauren Hoffman; Zhigang Fan; Andi Qipo; Hang Shi; Susan Bonner-Weir; Prabhakar Putheti; Nicolas Degauque; Towia A Libermann; Hugh Auchincloss; Jeffrey S Flier; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

10.  α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α.

Authors:  Angelia D Lockett; Samuel Kimani; Godfrey Ddungu; Sabine Wrenger; Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.